Know Cancer

or
forgot password

Phase II Study of Sunitinib in Metastatic Renal Cancer With Non-clear Cell Histology


Phase 2
18 Years
N/A
Open (Enrolling)
Both
Metastatic Renal Cancer With Non-clear Cell

Thank you

Trial Information

Phase II Study of Sunitinib in Metastatic Renal Cancer With Non-clear Cell Histology


Inclusion Criteria:



- Histologically proven diagnosis of metastatic renal cancer with non-clear cell

- No previous treatment

Exclusion Criteria:

- Prior treatment with an antiangiogenetic compound

- Symptomatic and/or unstable pre-existing brain metastases

- Severe or uncontrolled cardiovascular diseases

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

The antitumor activity in terms of progression free survival

Outcome Time Frame:

two years

Safety Issue:

No

Principal Investigator

Armando Santoro, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Istituto Clinico Humanitas

Authority:

Italy: Ministry of Health

Study ID:

ONC-2008-004

NCT ID:

NCT01034878

Start Date:

December 2009

Completion Date:

November 2011

Related Keywords:

  • Metastatic Renal Cancer With Non-clear Cell
  • Carcinoma, Renal Cell
  • Kidney Neoplasms

Name

Location